Tag Archives: congenital heart disease

Figure 1. Transthoracic echocardiogram showing cessation of flow in the descending aorta Figure 2. Three-dimensional reconstruction of computed tomography (CT) aortogram showing interruption of thoracic aorta Case An asymptomatic 28-year-old man with an incidental finding of hypertension at a routine visa renewal medical presented to outpatients for review and further investigation. Significant radiofemoral delay was found on palpation of pulses, and an ejection systolic murmur heard over the praecordium. Blood pressure was recorded as 190/70 mmHg, despite therapy including irbesartan 300 mg, amlodipine 5 mg and atenolol 50 mg. Transthoracic

European Society of Cardiology congress 2018, held in Munich Professor Jolien Roos-Hesselink, said: “Pregnancy is safe for most women with heart disease but for some it is too risky. Our study shows that fewer women with heart disease die or have heart failure during pregnancy than 10 years ago. However, nearly one in 10 women with pulmonary arterial hypertension died during pregnancy or early post-partum.” She added that pre-pregnancy counselling is crucial to identify women who should be advised against pregnancy, for instance in those with severe valvular heart disease, and to discuss the risks, options and to initiate timely treatment

It is, therefore, with interest that we read the meta-analysis of long-term survival of individuals born with CHD by Best and Rankin.4 Utilising population-based studies, they report a pooled one-year, five-year and 10-year survival for all CHD of 87%, 85.4% and 81.4%, respectively. The survival estimates for individual CHD lesions differed, with ‘high-risk lesions’, such as tricuspid atresia or common arterial trunk, having a poorer survival than ‘simple lesions’, such as atrial septal defect (ASD) or ventricular septal defect (VSD), confirming what is seen in clinical practice. There were some surprising findings, including a worse

Introduction In the first article, we discussed those anomalies that are usually encountered by chance at, or just prior to, implantation; patent foramen ovale/atrial septal defect, Ebstein’s anomaly and ventricular septal defect, and the potential problems that they may provide to the device implanter. In the second article, we discussed the challenge of device implantation in patients with more complex congenital structural cardiac defects, which the operator should be aware of prior to device implantation, including congenitally corrected L-transposition of great arteries, tetralogy of Fallot and tricuspid atresia/univentricular heart. I

Introduction In the previous article, we discussed those anomalies that are usually encountered by chance at, or just prior to, implantation: patent foramen ovale/atrial septal defect, Ebstein’s anomaly and ventricular septal defect, and the potential problems that they may provide to the device implanter. In this and the next article, we will discuss the challenge of device implantation in patients with more complex congenital structural cardiac defects, which the operator should be aware of prior to device implantation. In this paper we include congenitally corrected L-transposition of great arteries (L-TGA), tetralogy of Fallot and tricu

Introduction The vast majority of patients requiring pacemaker or defibrillator implantation have structurally normal hearts and patients with congenital cardiac abnormalities constitute only a small proportion. The latter can be divided into two groups. The first includes those with undiscovered congenital abnormalities, which do not give rise to symptoms or obvious physical signs, such as dextrocardia, persistent left-sided superior vena cava, atrial septal defect and patent foramen ovale. The second group includes those who are known to have structural cardiac abnormalities, such as Ebstein’s anomaly, ventricular septal defect, transposi

No content available

No content available

No content available

No content available